The Future of Transdermal and Microneedle Drug Delivery according to Ester Caffarel-Salvador

The Future of Transdermal and Microneedle Drug Delivery according to Ester Caffarel-Salvador, Associate Director, Regenerative Medicine, LEO Pharma A/S. In preparation for the Inaugural Transdermal and Microneedle Drug Delivery Conference
By: SMi Group
LONDON - Nov. 24, 2021 - PRLog -- Dr. Ester Caffarel-Salvador is a multidisciplinary scientist with a background in biotechnology and biochemistry. Dr. Caffarel-Salvador is now an Associate Director of Regenerative Medicine at LEO Pharma. She is passionate about advocating on career development for women in science and is an advisor and mentor at various academic and entrepreneurial programs, both locally and internationally.

Speaker Interview:

Microneedle patches are a popular area of research currently, what do you believe are the most important factors to consider when designing a microneedle patch? Do you believe we should be focusing on dissolvable patches?

"There is no "one-size-fits-all" for microneedle patches and it is important to understand the patient diversity and not put all the patients in the same bucket. The design of the patch depends on many factors, including the site of application and the drug to be delivered. These factors put a constraint on fabrication parameters, such as the length of the microneedles, the size of the patch needed, or the most suitable fabrication method.

Dissolvable patches pose a notable advantage compared to metal microneedles by obviating sharp waste, however, their drug loading capacity is limited. As researchers devise new ways to increase loading capacity, translating the dissolving microneedles systems to the market remains a challenge in the field because achieving consistent drug exposure levels in clinical studies has proven to be difficult. Reproducibility is key for microneedles to succeed."

What current hot topic will you be addressing in your presentation and what would you say makes it relevant to 2022?

"With the increasing number of microneedle-inspired oral devices in development and clinical trials that show success in delivering macromolecules orally, it is to be expected that the prevalence of oral devices in the clinic will increase in the upcoming years.

For this reason, my talk will be aimed at discussing the key challenges of delivering macromolecules in the gastrointestinal tract and how the use of microneedles in oral drug delivery devices can help circumvent such challenges."

The Conference:
SMi Group is proud to present the inaugural Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, in London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.

Sponsors of the conference include: LTS Lohmann Therapie-Systeme AG, QuadMedicine

Transdermal and Microneedle Delivery
24-25 January 2022
London, UK

Media Contact
Richard Jones
Posted By:*** Email Verified
Tags:Transdermal and Microneedle
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share